Tuesday, 28 Jan 2020

You are here

Respiratory Risks Not Increased in RA Patients with COPD

An insurance claims based study of rheumatoid arthritis (RA) patients with chronic obstructive pulmonary disease (COPD) shows that biologics do not have an increased rate of respiratory events compared to those on conventional DMARDs.

A real world cohort of RA patients with COPD was drawn from US-based MarketScan databases. Patients on biologic DMARDs and/or targeted synthetic DMARDs (tsDMARDs) were propensity matched to those on conventional synthetic DMARDs (csDMARDs).

The study compared 7424 RA/COPD patients initiating biologic/tsDMARDs to 7424 patients initiating csDMARDs.

Comparing biologic/tsDMARD vs csDMARD shows the adjusted hazard ratio for:

  • hospitalized COPD exacerbation = 0.76 (95% CI: 0.55, 1.06)
  • bronchitis = HR 1.02 (95% CI: 0.82, 1.27)
  • hospitalized pneumonia or influenza = 1.21 (95% CI: 0.92, 1.58)
  • outpatient pneumonia or influenza=  0.99 (95% CI: 0.87, 1.12)

The hazard ratio of the combined end point of COPD exacerbation, bronchitis and hospitalized pneumonia or influenza was 1.04 (95% CI: 0.89, 1.21).

Biologic and tsDMARDs appear to be safe to use in RA patients with COPD, having a low risk of adverse respiratory events.

The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

2019 EULAR Recommendations for the Management of Rheumatoid Arthritis

The 2019 update to the EULAR recommendations on the use of synthetic and biological disease-modifying antirheumatic drugs in rheumatoid arthritis (RA) have been published in Annals of Rheumatic Disease - highlighting the efforts of an international consensus committee effort. In the end, the task force put forth 5 overarching principles and 12 recommendations concerning use of conventional synthetic DMARDs, glucocorticoids, biological DMARDs, biosimilar DMARDs, and targeted synthetic DMARDs (the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib).

Low Risk of Inflammatory Arthritis in Hidradenitis Suppurativa Patients

JAMA Dermatology reports that after the onset and diagnosis of hidradenitis suppurativa (HS), such patients have a higher risk of certain forms inflammatory arthritis.

Best of 2019 - War on RA - Part 1: Walk on the Moon

It’s a great time to be a rheumatologist and to manage RA. But, if you keep doing what you’re doing, you’re going to keep getting what you’ve got.

Best of 2019 - War on RA - Part 3: Useless Drugs

We have options that are endless – we have 28 biologics in rheumatology; 19 approved for RA in the last 20 years, but 15 of these are me-too copies or biosimilars. We currently have 2 JAK inhibitors and may have 3 or 4 by year end. But what we really need is the right drug, at the right time, in the right patient – but how will we know.

Link Between Obstructive Lung Disease and Developing RA?

We all know that the microbiome in the gut may be very important for multiple immune diseases. However, new findings from the ACR, 2019 in Atlanta reinforce how important the interface is between the lungs and developing rheumatoid arthritis.